Supplementary Figure 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

MLA

Hiroto Inaba, et al. Supplementary Figure 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22448669.v1.

APA

Hiroto Inaba, Charles G. Mullighan, Jeffrey E. Rubnitz, Sheila Shurtleff, Eric J. Enemark, Scott R. Olsen, Geoffrey A. Neale, Jassada Buaboonnam, Douglas S. Zatechka, Shelley Orwick, Yong-Dong Wang, Eric I. Zimmerman, & Sharyn D. Baker. (2023). Supplementary Figure 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia. https://doi.org/10.1158/1078-0432.22448669.v1

Chicago

Hiroto Inaba, Charles G. Mullighan, Jeffrey E. Rubnitz, Sheila Shurtleff, Eric J. Enemark, Scott R. Olsen, Geoffrey A. Neale, et al. 2023. “Supplementary Figure 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia,” March. doi:10.1158/1078-0432.22448669.v1.